Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.65 |
| ▸ | MAPT | P10636 | 10/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.58 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10701562 | 0.88 | MTOR (0.83) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL24701133 | 0.88 | MTOR (0.83) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL24701354 | 0.87 | MTOR (0.81) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL6267516 | 0.87 | MTOR (1.00) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL29943849 | 0.87 | MTOR (1.00) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL24700862 | 0.87 | MTOR (0.81) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL24700848 | 0.84 | MTOR (0.93) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL24701302 | 0.83 | MTOR (0.80) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL24701383 | 0.81 | MTOR (0.80) | MTORRAB9ASIRT2ALDH1A1MAPT | |
| SCHEMBL28520810 | 0.80 | MTOR (0.64) | MTORRAB9ASIRT2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | ARRAKIS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220281860-A1 | COMPOUNDS AND METHODS OF TREATING RNA-MEDIATED DISEASES | NSUN3, NSUN2, POLRMT | MTOR 1869/4885RAB9A 1919/4885SIRT2 1924/4885 |
| US-20220402883-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION | NSUN3, NSUN2, METTL16 | MTOR 1926/4885RAB9A 2764/4885SIRT2 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.